Back

Agenus reports 48% estimated three-year survival with BOT+BAL at IGCS 2026

Verifying
  • Agenus reported estimated three-year survival with BOT+BAL in recurrent ovarian cancer.
  • 48% was the estimated three-year survival figure reported for BOT+BAL.
  • IGCS 2026 was the event named in the report.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.